N/A
N=41
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase
Opioid Use, Unspecified
Bottom Line
View on ClinicalTrials.gov: NCT03773484 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcome: Primary: Average Weekly Milligram Morphine Equivalent (MME) — 34.62; 22.37; NA Weekly MME per clinician — p=0.43
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Opioid naive (Behavioral); At-risk for long term use (Behavioral); Long-term opioid recipient (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Southern California
- Primary completion
- Nov 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Weekly Milligram Morphine Equivalent (MME) |
34.62; 22.37; NA | 0.43 |
Summary
There is a lack of evidence that long-term opioid use offers benefit for noncancer pain and an abundance of evidence of harm. The objective of the R21 pilot phase of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS) is to develop and test novel behavioral nudges to encourage adherence to pain and CDC guidelines for opioid prescribing for persons with noncancer pain. Interventions will leverage the electronic health record (EHR) to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.
Eligibility Criteria
Inclusion Criteria
- NM clinic that sees patients ≥ 18 years old whose leadership agrees to participate
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT03773484). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.